The long-term goal is to develop effective strategies for treating hormone-refractory (HR) prostate cancer (PCa). To accomplish this goal, the molecular mechanism by which advanced PCa cells escape from androgen requirement will be elucidated. Preliminary results showed that cellular prostatic acid phosphatase (cPAcP) and ErbB-2/HER-2/neu are involved in regulating androgen-stimulated cell proliferation. Decreased cPAcP correlates with androgen-independent (Al) growth of PCa cells, corroborating clinical phenomena. Further, p66Shc, an adaptor protein of ErbB-2, is elevated in PCa specimens and Al high passage (HP) LNCaP and MDA PCa2B cells. The working hypothesis is that aberrant ErbB-2 signaling, via p66Shc, represents one of functional pathways involving in hormone-refractory growth of PCa cells.
The specific aims are: 1. To determine the role of ErbB-2 in Al cell proliferation. This will be done by knocking down cPAcP expression with siRNA in androgen-sensitive (AS) low passage (LP) LNCaP and MDA PCa2b cells and analyze its effect on ErbB-2 activation and Al cell growth. Inhibition of cPAcP activity can also be done by transfecting LP cells with a cDNA encoding a negative mutant of cPAcP or culturing them in PAcP inhibitor. Al cell growth will also be examined in ErbB-2-knocked down cells by siRNA. Al phenotype will be confirmed in xenograft animals. The interaction between cPAcP and ErbB-2 will be determined by identifying the dephosphorylation sites. The mechanism by which butyrate up-regulates PAcP expression will be delineated. 2. To analyze p66Shc involvement in Al PCa cell proliferation. To elevate p66Shc expression, LP cells will be transfected with p66Shc cDNA and then androgen independence of transfected cells will be examined in culture and xenograft animals. Conversely, p66Shc will be knocked down by siRNA in HP cells and then androgen independence of those cells will be determined. The signaling pathway by which p66Shc up-regulates cell growth will be delineated. The mechanism by which p66Shc is elevated in Al cells will be investigated. 3. To correlate in vitro findings with clinical significance. The expression of p66Shc and cPAcP will be analyzed by immunohistochemistry staining of clinical archival specimens. The intensity and the extent of staining will be semi-quantified for calculating a composite score, which will be correlated with clinico-pathological progression of PCa, including HR PCa. ? ? ? ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA088184-08
Application #
7477121
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Poland, Alan P
Project Start
2000-07-01
Project End
2011-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
8
Fiscal Year
2008
Total Cost
$253,275
Indirect Cost
Name
University of Nebraska Medical Center
Department
Biochemistry
Type
Schools of Medicine
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chuang, Tsai-Der; Sakurai, Reiko; Gong, Ming et al. (2018) Role of miR-29 in Mediating Offspring Lung Phenotype in a Rodent Model of Intrauterine Growth Restriction. Am J Physiol Regul Integr Comp Physiol :
Ingersoll, Matthew A; Chou, Yu-Wei; Lin, Jamie S et al. (2018) p66Shc regulates migration of castration-resistant prostate cancer cells. Cell Signal 46:1-14
Miller, Dannah R; Tzeng, Cherng-Chyi; Farmer, Trey et al. (2018) Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. Cancer Lett 436:96-108
Ingersoll, Matthew A; Miller, Dannah R; Martinez, October et al. (2016) Statin derivatives as therapeutic agents for castration-resistant prostate cancer. Cancer Lett 383:94-105
Muniyan, Sakthivel; Chen, Siu-Ju; Lin, Fen-Fen et al. (2015) ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cell Signal 27:2261-71
Ingersoll, Matthew A; Lyons, Anastesia S; Muniyan, Sakthivel et al. (2015) Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells. PLoS One 10:e0131811
Chou, Yu-Wei; Lin, Fen-Fen; Muniyan, Sakthivel et al. (2015) Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. Cell Biosci 5:38
Lo, We-Fen; Chou, Yu-Wei; Tseng, Chih-Hua et al. (2015) Discovery of Novel N-alkyl 4-anilinofuro[2,3-b]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers. Anticancer Agents Med Chem 15:493-500
Muniyan, Sakthivel; Chou, Yu-Wei; Tsai, Te-Jung et al. (2015) p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Mol Carcinog 54:618-31
Muniyan, Sakthivel; Ingersoll, Matthew A; Batra, Surinder K et al. (2014) Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. Biochim Biophys Acta 1846:88-98

Showing the most recent 10 out of 64 publications